Indaptus reported a significant reduction in operating expenses for the second quarter of 2026 as the company effectively halted its active clinical development programs. Following the discontinuation of enrollment in its Decoy20 studies, the company is now pivoting toward a strategic review of its platform and exploring new research collaborations in neurological disorders.
Key Highlights
- Net loss narrowed to $1.8 million, or $0.02 per share, compared to a $5.2 million loss in the second quarter of 2025.
- Research and development expenses decreased 83% to $0.4 million, driven by the wind-down of the Decoy20 Phase 1 study and headcount reductions.
- Total liquidity improved to $11.6 million in cash and short-term investments following a $12.0 million private placement completed in June 2026.